文献速递前列腺癌

PARP抑制剂在前列腺癌中的应用时机与方式:系统综述及在研试验更新

When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
PubMed 文献 · Eur Urol Oncol · 2020-08-17

本系统综述检索2010年1月至2020年3月PubMed及主要会议文献,最终纳入18篇出版物,并识别15项尚未报告数据的2期或进行中的3期转移性去势抵抗性前列腺癌(mCRPC)研究。综述认为PARP抑制剂在携带同源重组修复(HRR)缺陷的mCRPC中疗效最佳,奥拉帕利和芦卡帕利已分别获FDA批准用于HRR突变和BRCA1/2突变的mCRPC患者。

要点

  • 单药PARP抑制剂在胚系或体细胞BRCA1/2改变(尤其BRCA2或双等位基因突变)的mCRPC中疗效最佳。
  • PALB2和FANCA突变患者也可能从PARP抑制剂中获益。
  • PARP抑制剂联合新型内分泌治疗时,无论HRR缺陷状态如何均可能观察到治疗获益。

核心结论

  • PARP抑制剂在mCRPC中显示出疗效,与卵巢癌和乳腺癌类似,HRR缺陷患者效果最大。
  • 奥拉帕利和芦卡帕利已分别获FDA批准用于HRR突变和BRCA1/2突变的mCRPC患者。
  • PARP抑制剂联合新型内分泌治疗时,无论HRR缺陷状态如何均可能观察到治疗获益。

研究设计与样本

  • 系统综述:检索PubMed及主要会议文献,时间范围为2010年1月至2020年3月。
  • 共识别168篇出版物,其中18篇符合后续综述标准。
  • 通过ClinicalTrials.gov识别15项评估PARP抑制剂单药或联合治疗的2期或进行中的3期mCRPC研究,尚未报告数据。

主要发现

  • 单药PARP抑制剂在携带胚系或体细胞BRCA1/2改变(尤其BRCA2或双等位基因突变)的mCRPC患者中疗效最大。
  • 在PALB2和FANCA突变男性中也观察到潜在疗效。
  • PARP抑制剂联合新型内分泌治疗时,无论HRR缺陷状态如何均可能观察到治疗获益。

关键数值与推荐

  • 奥拉帕利获FDA批准用于HRR突变的mCRPC患者。
  • 芦卡帕利获FDA批准用于BRCA1/2突变的mCRPC患者。

临床怎么用

  • 对mCRPC患者应检测HRR相关基因突变(尤其BRCA1/2),以筛选PARP抑制剂治疗获益人群。
  • PARP抑制剂联合新型内分泌治疗可能不受HRR缺陷状态限制,但需进一步研究确认。

局限性

  • 识别HRR突变的最适当诊断检测方法尚未明确。
  • 围绕PARP抑制剂在前列腺癌中使用的知识和理解仍存在差距。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The goal of precision oncology is to use the underlying genomic characteristics of the patient and the cancer to select the optimal treatment at a given time. The recent Food and Drug Administration (FDA) approval of the poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and rucaparib for the treatment of advanced prostate cancer heralds the onset of precision medicine for this disease. OBJECTIVE: To discuss the emerging role that PARP inhibitors may play as a personalised future treatment option in patients with prostate cancer, with a focus on patients with metastatic castration-resistant prostate cancer (mCRPC) whose tumour cells harbour mutations resulting from deficient homologous recombination repair (HRR). EVIDENCE ACQUISITION: To identify publications relevant to this review, a systematic literature search of PubMed was conducted for articles and proceedings of relevant major congresses, published between January 2010 and March 2020, reporting the use of PARP inhibitors in the treatment of cancers. EVIDENCE SYNTHESIS: A total of 168 publications were identified, and 18 of these met the criteria for subsequent review. In addition, 15 phase 2 or on-going phase 3 (mCRPC) studies evaluating PARP inhibitors as monotherapy or in combination, which had not yet reported data, were identified through ClinicalTrials.gov. Emerging data suggest that the greatest efficacy with single-agent PARP inhibitors is seen in mCRPC patients with germline or somatic BRCA1/2 alterations (especially BRCA2 or biallelic mutations), with potential efficacy also observed in men with PALB2 and FANCA mutations. CONCLUSIONS: PARP inhibitors have demonstrated efficacy in mCRPC, and similar to ovarian and breast cancers, the greatest effect is observed in patients with HRR deficiency. The PARP inhibitors olaparib and rucaparib are now FDA approved for mCRPC patients with HRR mutations and BRCA1/2 mutations, respectively. Furthermore, when PARP inhibition is combined with novel hormonal therapies, a treatment benefit may be observed regardless of the HRR deficiency status. Gaps in the knowledge and understanding around PARP inhibitor use in prostate cancer, including the most appropriate diagnostic testing method for identifying an HRR mutation, remain to be resolved. PATIENT SUMMARY: The poly(ADP-ribose) polymerase (PARP) inhibitors olaparib and rucaparib are now approved by the Food and Drug Administration for the treatment of advanced prostate cancer. Here, we reviewed the literature and proceedings from meeting presentations and published papers relevant to the use of PARP inhibitors in the treatment of prostate cancer. Testing methods for detecting homologous recombination repair gene mutations, as diagnostic tools to help identify patients most likely to benefit from PARP inhibitor treatment, are also discussed.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Antonarakis ES, Gomella LG, Petrylak DP, et al. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. Eur Urol Oncol. 2020. PMID: 32814685. doi:10.1016/j.euo.2020.07.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。